Their story
2 decades of liver health. Since its creation in 2001, Echosens has continued to develop its core technology: controlled vibration transient elastography, known as VCTE™, through a unique portfolio of solutions.
The best known alternatives to liver biopsy, FibroScan® parameters (VCTE™ and CAP™) have led Echosens to sustained growth in France and abroad since its early days, with more than 90% of sales generated abroad.
Given the high prevalence of chronic liver diseases, and in particular the silent epidemic of MASLD-MASH, Echosens is pursuing its technological and clinical research in order to provide healthcare professionals and pharmaceutical companies with continued innovation.